Clinical Trials Logo

Clinical Trial Summary

Single-arm phase II trial of 70 men with low- or intermediate-risk prostate cancer receiving magnetic resonance guided adaptive radiotherapy (MRgRT) in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, the internal pudendal arteries, the corpora cavernosa, and the penile bulb for erectile function preservation.


Clinical Trial Description

Rationale: Erectile dysfunction is a frequent side effect of external beam radiotherapy (EBRT) for prostate cancer. To date, anatomy-based treatments that are designed to spare relevant neurovascular structures such as the internal pudendal artery and neurovascular bundles have not yet been routinely implemented in clinical practice. The implementation of magnetic resonance imaging (MRI) in treatment planning and introduction of Intensity Modulated Radiotherapy (IMRT) and Volumetric Arc Therapy (VMAT) have improved treatment precision and enabled anatomy-based EBRT and neurovascular-sparing treatments. Spratt et al. have conducted a single-arm phase 2 study to investigate the effect of vascular-sparing IMRT treatments, and found a significantly improved 2-year erectile function (78%, 95% confidence interval [CI] 71-85%) compared to conventional radiotherapy (42%, 95% CI 38-45%; p<0.001) or nerve-sparing prostatectomy (24%, 95% CI 22-27%; p<0.001). In the UMCU, the state-of-the-art MRI linear accelerator (MR-Linac) has recently been introduced. This new system allows radiation delivery under high-precision MRI visualization. The MR-Linac is therefore the most suitable technique for neurovascularsparing external beam radiotherapy treatments. Such neurovascular-sparing treatments may substantially improve post-radiotherapy erectile function outcomes and can thus improve quality of life without substantially compromising oncologic outcome. Objective: To investigate preservation of erectile function after MR-guided radiotherapy with neurovascular-sparing in patients with localized prostate cancer. Study design: The EREctile function preservation for prostate Cancer radiation Therapy (ERECT) trial is a prospective, single-center, phase 2 trial. Patients will be treated with the MR-Linac up to 5 fractions of 7.25 Gy with neurovascular-sparing. All fractions will be delivered over the course of 2 and a half weeks. Study population: Men with low- and intermediate-risk adenocarcinoma of the prostate, clinical stage T1c-T2c, and Gleason ≤7, and iPSA <20 µg/L (NCCN risk categories). Patients with pT1a/b tumor diagnosis after transurethral resection of the prostate (TURP) are included, patients with "bulky" iT3 tumor diagnosis are excluded. Baseline erectile function score according to the International Index of Erectile Function (IIEF-5) questionnaire of at least 17. Intervention: All patients will receive MR-Linac treatment consisting of 5 fractions of 7.25 Gy with neurovascular sparing, Fractions will be delivered with an overall treatment time of two and a half weeks. Main study parameters/endpoints: Primary endpoint: the incidence of erectile dysfunction (ED) three years after treatment. Secondary endpoints: relapse-free survival, acute and late genitourinary and gastrointestinal toxicity and patient reported quality of life. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants will receive neurovascular sparing MR guided radiation therapy (MRgRT) consisting of 5 fractions of 7.25 Gy. The number of fractions and duration of treatment is similar to conventional MRgRT consisting of 5 fractions of 7.25 Gy. No increase in toxicity is expected as the dose constraints for the organs at risk in the neurovascular sparing plan will be identical to the conventional plan (i.e. bladder, rectum, femoral head and anal sphincter). For neurovascular sparing treatment, the protocol is extended with dose constraints for newly identified organs at risk (i.e. neurovascular bundles (NVB), internal pudendal arteries (IPA), corpora cavernosa (CC) and penile bulb (PB)). Attention for these organs at risk during treatment planning may reduce erectile dysfunction for the neurovascular sparing treatment. The dose to the dorsolateral part of the prostate might be lower in the NVB sparing plan as the NVB lies in close proximity to this part of the prostate. A slight dose concession on the dorsolateral part of the prostate will only be permitted if the visible tumor on multiparametric MRI is not in vicinity of the NVB as underdosage of the dominant index lesion is undesirable for tumor control. A lower dose to the dorsolateral part of the prostate may have an impact on biochemical control for certain cases, but we do not expect that it will influence overall survival. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04861194
Study type Interventional
Source UMC Utrecht
Contact Frederik R Teunissen, MD
Phone +31 (0)887550474
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date May 18, 2021
Completion date May 18, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04081636 - Prostate Biopsy: Efficacy and Complications N/A
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Recruiting NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Active, not recruiting NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A
Active, not recruiting NCT00499421 - Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation Therapy
Recruiting NCT03668652 - Focal Prostate Ablation Versus Radical Prostatectomy N/A
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A
Recruiting NCT03700099 - Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide Phase 2
Recruiting NCT04219059 - MR Radiomic Features in Prostate Cancer
Recruiting NCT04249154 - Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer Phase 2
Recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT00953576 - Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer Phase 1/Phase 2
Recruiting NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1